Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 10 , Pages 1105-1113 , October 2008

Psychopharmacological Treatment Options for Global Child and Adolescent Mental Health: The WHO Essential Medicines Lists

,Accepted 10 April 2008.

References 

  1. Remschmidt H , Belfer M . Mental health care for children and adolescents worldwide: a review . World Psychiatry . 2005;4:147–153
  2. World Health Organization  . Caring for Children and Adolescents With Mental Disorders: Setting WHO Directions . Geneva: World Health Organization; 2003;
  3. Gould MS , Greenberg T , Velting DM , Shaffer D . Youth suicide risk and preventive interventions: a review of the past 10 years . J Am Acad Child Adolesc Psychiatry . 2003;42:386–405
  4. Shatkin JP , Belfer ML . The global absence of child and adolescent mental health policy . Child Adolesc Ment Health . 2004;9:104–108
  5. Belfer ML . Child and adolescent mental disorders: the magnitude of the problem across the globe . J Child Psychol Psychiatry . 2008;49:226–236
  6. World Health Organization  , World Psychiatric Association  . Presidential Global Programme on child and Adolescent Mental Health, International Association for Child and Adolescent Mental Health and Allied Professions . Atlas: Child and Adolescent Mental Health Resources: Global Concerns, Implications for the Future . Geneva: World Health Organization; 2005;
  7. Funk M , World Health Organization  . Child and Adolescent Mental Health Policies and Plans . Geneva: World Health Organization; 2005;
  8. Everard M , World Health Organization  . Improving Access and Use of Psychotropic Medicines . Geneva: World Health Organization; 2005;
  9. Kutcher S, Gardner DM. Course: Rational Psychopharmacotherapy in Mentally Ill Youth. 18th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professionals. Istanbul, April 30-May 1, 2008.
  10. WHO  . Rational Use of Medicines: Activities . http://www.who.int/medicines/areas/rational-use/rud-activities/en/index.html Accessed January 29, 2008.
  11. WHO  . Selection and Rational Use of Medicines . http://www.who.int/medicines/areas/rational-use/en/index.html Accessed January 28, 2008.
  12. World Health Organization  . WHO model list of essential medicines for children . http://www.who.int/medicines/publications/essentialmedicines/en/index.html October 2007;
  13. Laing R , Waning B , Gray A , Ford N , 't Hoen E . 25 years of the WHO essential medicines lists: progress and challenges . Lancet . 2003;361:1723–1729
  14. Oxman AD , Lavis JN , Fretheim A . Use of evidence in WHO recommendations . Lancet . 2007;369:1883–1889
  15. Braine T . WHO to launch first essential medicines list for children . Bull World Health Organ . 2007;85:249–250
  16. Zucker H , Rago L . Access to essential medicines for children: the World Health Organization's global response . Clin Pharmacol Ther . 2007;82:503–505
  17. World Health Organization  . Mental Health Atlas: 2005 . Geneva: World Health Organization; 2005;
  18. Rosenburg DR , Davanzo PA , Gershon S . Pharmacotherapy for Child and Adolescent Psychiatric Disorders . 2nd ed.. New York: Marcel Dekker; 2002;
  19. Preston J , O'Neal JH , Talaga MC . Child and Adolescent Clinical Psychopharmacology Made Simple . Oakland, CA: New Harbinger Publications; 2006;
  20. Kutcher SP . Practical Child and Adolescent Psychopharmacology . New York: Cambridge University Press; 2002;
  21. Green WH . Child and Adolescent Clinical Psychopharmacology . Philadelphia: Lippincott Williams & Wilkins; 2007;
  22. Connor DF , Meltzer BM . Pediatric Psychopharmacology: Fast Facts . New York: W.W. Norton; 2006;
  23. Bezchlibnyk-Butler KZ , Virani AS . Clinical Handbook of Psychotropic Drugs for Children and Adolescents . 2nd rev. ed.. Toronto: Hogrefe & Huber; 2007;
  24. Tosyali MC , Greenhill LL . Child and adolescent psychopharmacology. Important developmental issues . Pediatr Clin North Am . 1998;45:1021–1035
  25. Murrin LC , Sanders JD , Bylund DB . Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: implications for differential drug effects on juveniles and adults . Biochem Pharmacol . 2007;73:1225–1236
  26. Bylund DB , Reed AL . Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs? . Neurochem Int . 2007;51:246–253
  27. Anderson IM . Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability . J Affect Disord . 2000;58:19–36
  28. Wilson K , Mottram P . A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis . Int J Geriatr Psychiatry . 2004;19:754–762
  29. Hazell P , O'Connell D , Heathcote D , Henry D . Tricyclic drugs for depression in children and adolescents . Cochrane Database Syst Rev . 2002;2:CD002317
  30. Patel V , Flisher AJ , Hetrick S , McGorry P . Mental health of young people: a global public-health challenge . Lancet . 2007;369:1302–1313
  31. Wolraich ML , Wibbelsman CJ , Brown TE , et al.   Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications . Pediatrics . 2005;115:1734–1746
  32. Brown RT , Amler RW , Freeman WS , et al.   Treatment of attention-deficit/hyperactivity disorder: overview of the evidence . Pediatrics . 2005;115:e749–e757
  33. Pliszka S , AACAP Work Group on Quality Issues  . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder . J Am Acad Child Adolesc Psychiatry . 2007;46:894–921
  34. Geller DA , Biederman J , Stewart SE , et al.   Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder . Am J Psychiatry . 2003;160:1919–1928
  35. Donnelly CL , Amaya-Jackson L . Post-traumatic stress disorder in children and adolescents: epidemiology, diagnosis and treatment options . Paediatr Drugs . 2002;4:159–170
  36. Donnelly CL . Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder . Child Adolesc Psychiatr Clin N Am . 2003;12:251–269
  37. Ipser J , Seedat S , Stein DJ . Pharmacotherapy for post-traumatic stress disorder—a systematic review and meta-analysis . S Afr Med J . 2006;96:1088–1096
  38. Stein DJ , Ipser JC , Seedat S . Pharmacotherapy for post traumatic stress disorder (PTSD) . Cochrane Database Syst Rev . 2006;1:CD002795
  39. Seedat S , Stein DJ , Ziervogel C , et al.   Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder . J Child Adolesc Psychopharmacol . 2002;12:37–46
  40. Cohen JA , Mannarino AP , Perel JM , Staron V . A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms . J Am Acad Child Adolesc Psychiatry . 2007;46:811–819
  41. The Pediatric OCD Treatment Study (POTS) Team  . Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial . JAMA . 2004;292:1969–1976
  42. Wagner KD , Cook EH , Chung H , Messig M . Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder . J Child Adolesc Psychopharmacol . 2003;13:S53–S60
  43. Thompson JK , Smolak L . Body Image, Eating Disorders, and Obesity in Youth: Assessment, Prevention, and Treatment . Washington, DC: American Psychological Association; 2001;
  44. Lask B , Bryant-Waugh R . Anorexia Nervosa and Related Eating Disorders in Childhood and Adolescence . 2nd ed.. Hove, UK: Psychology Press; 2000;
  45. Hindmarch D . Eating Disorders: A Multiprofessional Approach . London, Philadelphia: Whurr; 2000;
  46. Gowers SG . Management of eating disorders in children and adolescents . Arch Dis Child . 2008;93:331–334
  47. Gowers S , Bryant-Waugh R . Management of child and adolescent eating disorders: the current evidence base and future directions . J Child Psychol Psychiatry . 2004;45:63–83
  48. Wilson GT , Shafran R . Eating disorders guidelines from NICE . Lancet . 2005;365:79–81
  49. Berkman ND , Bulik CM , Brownley KA , et al.   Management of eating disorders . Evid Ref Technol Assess (Full Rep) . 2006;135:1–166
  50. Walsh BT , Kaplan AS , Attia E , et al.   Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial . JAMA . 2006;295:2605–2612
  51. Holtkamp K , Konrad K , Kaiser N , et al.   A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy . J Psychiatr Res . 2005;39:303–310
  52. Berkman ND , Lohr KN , Bulik CM . Outcomes of eating disorders: a systematic review of the literature . Int J Eat Disord . 2007;40:293–309
  53. Romano SJ , Halmi KA , Sarkar NP , Koke SC , Lee JS . A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment . Am J Psychiatry . 2002;159:96–102
  54. Ipser J , Stein DJ . Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents . Psychopharmacology (Berl) . 2007;191:127–140
  55. Scott LJ , Dhillon S . Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents . Paediatr Drugs . 2007;9:343–354
  56. FDA News  . FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal . Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01485.html Accessed February 24, 2008.
  57. Chavez B , Chavez-Brown M , Rey JA . Role of risperidone in children with autism spectrum Disorder . Ann Pharmacother . 2006;40:909–916
  58. Stachnik JM , Nunn-Thompson C . Use of atypical antipsychotics in the treatment of autistic disorder . Ann Pharmacother . 2007;41:626–634
  59. Nagaraj R , Singhi P , Malhi P . Risperidone in children with autism: randomized, placebo-controlled, double-blind study . J Child Neurol . 2006;21:450–455
  60. Shea S , Turgay A , Carroll A , et al.   Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders . Pediatrics . 2004;114:e634–e641
  61. Jesner OS , Aref-Adib M , Coren E . Risperidone for autism spectrum disorder . Cochrane Database Syst Rev . 2007;1:CD005040
  62. Libby AM , Brent DA , Morrato EH , Orton HD , Allen R , Valuck RJ . Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs . Am J Psychiatry . 2007;164:884–891
  63. Bridge JA , Iyengar S , Salary CB , et al.   Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials . JAMA . 2007;297:1683–1696
  64. Hetrick S , Merry S , McKenzie J , Sindahl P , Proctor M . Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents . Cochrane Database Syst Rev . 2007;3:CD004851
  65. Kaizar EE , Greenhouse JB , Seltman H , Kelleher K . Do antidepressants cause suicidality in children? A bayesian meta-analysis . Clin Trials . 2006;3:73–90
  66. Mann JJ , Emslie G , Baldessarini RJ , et al.   ACNP task force report on SSRIs and suicidal behavior in youth . Neuropsychopharmacology . 2006;31:473–492
  67. Dubicka B , Hadley S , Roberts C . Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis . Br J Psychiatry . 2006;189:393–398
  68. Kutcher S , Gardner DM . Use of selective serotonin reuptake inhibitors and youth suicide: making sense from a confusing story . Curr Opin Psychiatry . 2008;21:65–69
  69. Hammad TA , Laughren T , Racoosin J . Suicidality in pediatric patients treated with antidepressant drugs . Arch Gen Psychiatry . 2006;63:332–339
  70. March J , Silva S , Petrycki S , et al.   Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial . JAMA . 2004;292:807–820
  71. Emslie GJ , Kennard BD , Mayes TL , et al.   Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents . Am J Psychiatry . 2008;165:459–467
  72. Graham ID , Beardall S , Carter AO , et al.   What is the quality of drug therapy clinical practice guidelines in Canada? . CMAJ . 2001;165:157–163
  73. Murphy AL , Gardner DM , Kutcher S . Med Ed—Medication Education for Promoting Mental Wellness: A Guide for Young People and Those Who Care for Them . Toronto: TAC Associates; 2008;
  74. American Academy of Child and Adolescent Psychiatry  . Training and education . http://www.aacap.org/cs/root/physicians_and_allied_professionals/training_and_education Accessed March 28, 2008.
  75. New England Education Institute  . Clinical Psychopharmacology: Overview and Recent Advances . http://www.neei.org/workshops/conference-details.aspx?WID=2&CID=97 Accessed March 28, 2008.
  76. WHO  . In: The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2007 . Vol. 946: Geneva: World Health Organization; 2007;
  77. Kutcher S , Chehil S , Cash C , Millar J . A competencies-based mental health training model for health professionals in low and middle income countries . World Psychiatry . 2005;4:177–180

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.

PII: S0890-8567(08)60094-5

doi: 10.1097/CHI.0b013e3181825ae1

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 10 , Pages 1105-1113 , October 2008

Article Tools